We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+30%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$1.11B
AUM Growth
+$235M
Cap. Flow
+$32.1M
Cap. Flow %
2.9%
Top 10 Hldgs %
76.43%
Holding
31
New
9
Increased
4
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$46.4M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$19M
3
IMMU
Immunomedics Inc
IMMU
+$14.7M
4
INSM icon
Insmed
INSM
+$13.8M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$9.57M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$33.9M
2
RDUS
Radius Health, Inc.
RDUS
+$22.5M
3
NGNE icon
Neurogene
NGNE
+$19.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.7M
5
AKBA icon
Akebia Therapeutics
AKBA
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 99.09%
2 Miscellaneous 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
26
Protara Therapeutics
TARA
$222M
$2.67M 0.24%
33,437
– –
AKBA icon
27
Akebia Therapeutics
AKBA
$250M
– –
-836,337
Closed -$12M
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
– –
-731,531
Closed -$33.9M
NGNE icon
29
Neurogene
NGNE
$674M
– –
-69,804
Closed -$19.6M
RDUS
30
DELISTED
Radius Health, Inc.
RDUS
– –
-497,157
Closed -$22.5M
1
2

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, RA Capital Management held 31 positions worth $1.11B, up 27% from $871M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

RA Capital Management's Q3 2017 filing shows 9 new, 4 increased, 3 reduced and 4 closed positions. Its largest new stake was KALA BIO: 846 shares worth $48.3M. The largest sale was Esperion Therapeutics, an estimated $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RA Capital Management's largest Q3 2017 buy was KALA BIO: 846 shares worth $48.3M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q3 2017, an estimated $9.33M increase.
  • RA Capital Management's biggest Q3 2017 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $13.7M.
  • RA Capital Management fully exited Esperion Therapeutics in Q3 2017, selling an estimated $33.9M.
  • RA Capital Management's ten largest holdings make up 76% of its $1.11B portfolio in Q3 2017.
  • RA Capital Management opened 9 new positions and closed 4 in Q3 2017.
  • RA Capital Management's portfolio value rose 27% quarter-over-quarter to $1.11B.

Based on RA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.